Sinco Pharmaceutical Holdings (HKSE:06833) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06833 Sinco Pharmaceutical Holdings Ltd HKSE:06833
44 GF Score
Price HK$0.17
GF Value HK$0.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sinco Pharmaceutical Holdings LT-Debt-to-Total-Asset?

Sinco Pharmaceutical Holdings HKSE:06833 -0.60% 44 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sinco Pharmaceutical Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Sinco Pharmaceutical Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.00) to Dec. 2025 (0.00). It may suggest that Sinco Pharmaceutical Holdings is progressively becoming less dependent on debt to grow their business.

Sinco Pharmaceutical Holdings  (HKSE:06833) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sinco Pharmaceutical Holdings LT-Debt-to-Total-Asset Related Terms

Sinco Pharmaceutical Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sinco Pharmaceutical Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinco Pharmaceutical Holdings LT-Debt-to-Total-Asset Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.01 0.00 0.00 0.00

Sinco Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:06833
44GF Score
Sinco Pharmaceutical Holdings Ltd HKSE:06833
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinco Pharmaceutical Holdings LT-Debt-to-Total-Asset Calculation

Sinco Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.536/2040.352
=0.00

Sinco Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0.536/2040.352
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Sinco Pharmaceutical Holdings (HKSE:06833) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sinco Pharmaceutical Holdings and its competitors.
Is Sinco Pharmaceutical Holdings' LT-Debt-to-Total-Asset too high?
Sinco Pharmaceutical Holdings' current LT-Debt-to-Total-Asset is 0.00. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' LT-Debt-to-Total-Asset compare to MCK and COR?
Sinco Pharmaceutical Holdings' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Distribution company?
A good LT-Debt-to-Total-Asset depends on the Medical Distribution industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sinco Pharmaceutical Holdings and its competitors. Sinco Pharmaceutical Holdings's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?

Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19. GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:06833:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinco Pharmaceutical Holdings Business Description

Address No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score

Get the complete analysis for HKSE:06833

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.17
Price
HK$0.19
GF Value